The U.S. Supreme Court on Monday declined to hear Novartis Pharmaceuticals Corp s bid to revive a key patent on its blockbuster multiple sclerosis drug Gilenya that was invalidated amid a legal. | April 17, 2023
Chief Justice Roberts granted Novartis’s emergency request for a stay of a mandate from US Court of Appeals for the Federal Circuit, which found a Novartis patent invalid for lack of adequate written description and permitted production of generic versions of drug Gilenya.
Novartis AG plans to ask the U.S. Supreme court to uphold the validity of a patent it holds on the dosing regimen for multiple sclerosis drug Gilenya after suffering a setback in a federal appeals. | September 21, 2022